Related Experiment Video

Updated: Aug 10, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

[Octreotide therapy for persistent hyperinsulinemic hypoglycemia of infancy]

Dênis Paiva Ferraz1, Marco Aurélio S Almeida, Bernardo Freire de Mello

  • 1Serviço de Endocrinologia, Santa Casa de Misericórdia de Juiz de Fora, MG.

Arquivos Brasileiros De Endocrinologia E Metabologia
|March 18, 2006
PubMed

Insights

Persistent hyperinsulinemic hypoglycemia of infancy (PHHI) is a serious condition. Octreotide offers a viable treatment option before surgery, crucial for infant neurodevelopment.

Area of Science:

  • Pediatric Endocrinology
  • Neonatology
  • Surgical Gastroenterology

Background:

  • Persistent hyperinsulinemic hypoglycemia of infancy (PHHI) is the leading cause of persistent hyperinsulinism in infants.
  • PHHI poses significant risks to central nervous system development.
  • Limited effective clinical treatment options exist for PHHI.

Observation:

  • A case report of a newborn experiencing hypoglycemic episodes within 24 hours of birth.
  • Successful initial management of the infant's condition using octreotide.
  • The case highlights the challenges in managing PHHI.

Findings:

  • Octreotide demonstrated efficacy as a pre-surgical treatment for PHHI.
  • Preoperative evaluation is critical for differentiating focal and diffuse pancreatic disease.
  • Distinguishing between focal and diffuse PHHI guides surgical approach and improves outcomes.

Implications:

  • Octreotide represents a valuable therapeutic option for PHHI prior to surgical intervention.
  • Accurate preoperative assessment is essential for optimizing surgical resection and minimizing complications.
  • Partial pancreatectomy is the preferred surgical method for focal PHHI, enhancing patient outcomes.

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Hyperosmolar Hyperglycemic State01:21

Hyperosmolar Hyperglycemic State

Hyperosmolar Hyperglycemic State, or HHS, is a serious and life-threatening complication of type 2 diabetes mellitus. It is characterized by three main features: severe hyperglycemia, profound dehydration, and elevated serum osmolality, all occurring without significant ketoacidosis.HHS typically develops in older adults or individuals with limited access to fluids. This may result from illness, cognitive impairment, or medications such as diuretics or corticosteroids. These factors reduce...